YIH
RVNC

Y-Intercept (HK)’s Revance Therapeutics, Inc. RVNC Stock Holding History

Y-Intercept (HK)’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-70,095
Closed -$345K – 2030
2024
Q1 		$345K Buy
+70,095
New +$415K 0.03% 893
2023
Q2 		– Sell
-10,009
Closed -$322K – 1811
2023
Q1 		$322K Buy
+10,009
New +$312K 0.04% 734

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Y-Intercept (HK)'s RVNC Position: Q2 2024 in Review

Y-Intercept (HK) sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2024, closing a stake of 70,095 shares — an estimated $345K sold.

Y-Intercept (HK) first reported a position in RVNC in Q1 2023 and held it in 2 quarters. The position peaked at $345K in Q1 2024. 173 funds tracked by Wall St. Rank hold RVNC as of Q2 2024.

  • Y-Intercept (HK) reported no remaining Revance Therapeutics, Inc. position as of Q2 2024 after selling out during the quarter.
  • Y-Intercept (HK) sold 70,095 Revance Therapeutics, Inc. shares in Q2 2024, an estimated $345K.
  • Y-Intercept (HK) first reported a position in Revance Therapeutics, Inc. in Q1 2023 and held it in 2 quarters.
  • Y-Intercept (HK)'s Revance Therapeutics, Inc. position peaked at $345K in Q1 2024.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2024.

Based on Y-Intercept (HK)'s 13F filing for Q2 2024, filed 14 Aug 2024.